Stem Cell Umbilical Cord Blood Market Report 2026

The stem cell umbilical cord blood market size has grown rapidly in recent years. It will grow from $7.98 billion in 2025 to $9.39 billion in 2026 at a compound annual growth rate (CAGR) of 17.7%. The growth in the historic period can be attributed to increased use of stem cell transplants, expansion of public cord blood banks, advancements in hematological treatments, growing awareness of stem cell therapies, improved neonatal healthcare infrastructure.

The stem cell umbilical cord blood market size is expected to see rapid growth in the next few years. It will grow to $17.83 billion in 2030 at a compound annual growth rate (CAGR) of 17.4%. The growth in the forecast period can be attributed to increasing demand for personalized regenerative therapies, rising investments in cell therapy research, expansion of neurological and immune disorder treatments, growing adoption of hybrid banking models, advancements in stem cell expansion technologies. Major trends in the forecast period include increasing adoption of advanced cryopreservation technologies, rising utilization of stem cells in regenerative medicine, growing expansion of private cord blood banking services, enhanced focus on cell quality and viability preservation, expansion of hybrid cord blood storage models.

The rising childbirth rates are expected to drive the growth of the stem cell umbilical cord blood market in the coming years. Childbirth rates refer to the number of live births per 1,000 individuals within a population over a specified period, typically one year. The increase in childbirth rates is primarily due to the greater accessibility and affordability of fertility treatments, allowing more families to have children. Umbilical cord blood stem cells are highly valuable for newborns, as they contain hematopoietic stem cells capable of treating various blood, immune, and genetic disorders. These cells are a perfect genetic match for the baby and can potentially benefit siblings or other family members. For instance, in April 2025, according to the U.S. Centers for Disease Control and Prevention, a U.S.-based federal agency, the number of births in the United States rose from 3,596,017 in 2023 to 3,622,673 in 2024, reflecting a 1% increase. Therefore, the rising childbirth rates are driving the growth of the stem cell umbilical cord blood market.

Major companies in the stem cell umbilical cord blood market are focusing on developing innovative therapies and obtaining regulatory approvals, such as cord blood cell therapy, to treat rare genetic disorders, support immune system recovery, and advance regenerative medicine applications. Cord blood cell therapy involves using stem cells derived from umbilical cord blood to regenerate or repair damaged blood, immune, and other tissues for treating various diseases. For instance, in October 2024, StemCyte, a US-based biotechnology company, received the regenerative medicine advanced therapy designation from the U.S. Food and Drug Administration (FDA) for its hematopoietic progenitor cell cord blood therapy (HPC Cord Blood) for the treatment of Long COVID-19 syndrome. This therapy utilizes umbilical cord blood stem cells to promote healing and reduce inflammation, showing potential in treating immune-related and degenerative conditions while providing a non-invasive, ethically sourced option for advanced regenerative treatments.

In July 2023, Leukaemia & Myeloma Research UK, a UK-based stem cell therapy organization, partnered with Smart Cells International to provide funded cord blood stem cell storage. This collaboration aims to give families a reliable and effective way to collect and preserve umbilical cord blood stem cells for future medical use and research. Smart Cells International is a UK-based biotechnology company specializing in the collection and storage of umbilical cord blood stem cells.

Major companies operating in the stem cell umbilical cord blood market are Global Cord Blood Corporation, Vita 34 AG, Cordlife Group Limited, StemLife Berhad, MediPost Co Ltd, Smart Cells International Ltd, StemCyte Inc, Celularity Inc, Next Biosciences Pty Ltd, Esperite NV, Cryo Cell International Inc, FamiCord Group, Cells4Life Group LLP, Cryoviva Biotech Pvt Ltd, Americord Registry LLC, ViaCord LLC, China Cord Blood Corporation, CBR Systems Inc, Cord Blood Registry, LifeCell International Pvt Ltd, CryoSave India Pvt Ltd.

North America was the largest region in the stem cell umbilical cord blood market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the stem cell umbilical cord blood market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the stem cell umbilical cord blood market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the stem cell umbilical cord blood market by increasing costs of imported cryogenic storage systems, laboratory equipment, consumables, and cell processing technologies used in banking and preservation services. Research institutes and private cord blood banks in North America and Europe are most affected due to reliance on imported high-precision equipment, while Asia-Pacific faces higher costs for export-oriented services. These tariffs are raising operational costs and slowing infrastructure expansion. However, they are also encouraging domestic equipment manufacturing, localized biobanking infrastructure development, and regional innovation in stem cell processing technologies.

The stem cell umbilical cord blood market research report is one of a series of new reports that provides stem cell umbilical cord blood market statistics, including stem cell umbilical cord blood industry global market size, regional shares, competitors with a stem cell umbilical cord blood market share, detailed stem cell umbilical cord blood market segments, market trends and opportunities, and any further data you may need to thrive in the stem cell umbilical cord blood industry. This stem cell umbilical cord blood market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Umbilical cord blood stem cells are specialized cells collected from the blood remaining in the umbilical cord and placenta after childbirth. This blood is rich in hematopoietic stem cells (HSCs), which have the ability to develop into all types of blood cells, including red blood cells, white blood cells, and platelets. These stem cells are used in medical treatments, such as bone marrow transplants, for patients with blood-related conditions including leukemia, lymphoma, and certain genetic disorders.

The primary components of stem cell umbilical cord blood include cord blood stem cells and cord tissue stem cells. Cord blood stem cells are blood-forming stem cells collected from a newborn’s umbilical cord and are used to treat blood and immune disorders. Technologies applied in processing these stem cells include cryopreservation, stem cell expansion, and cell separation. Storage services are categorized into public cord blood banks, private cord blood banks, and hybrid cord blood banks. The main applications include hematological disorders, metabolic diseases, immune system disorders, neurological disorders, and others. These stem cells serve various end users, including hospitals, research institutes, biotechnology companies, and other healthcare and research facilities.

The stem umbilical cord blood market consists of revenues earned by entities by providing services such as collection services, processing, testing, cryopreservation, storage, and transportation of cord blood, as well as related genetic screening and stem cell banking services. The market value includes the value of related goods sold by the service provider or included within the service offering. The stem umbilical cord blood market also includes sales of whole cord blood units, isolated stem cell products, and cord blood expansion kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.